MedTrace Logo

Safety and Efficacy of iDose® TR With Cataract Surgery vs. Cataract Surgery Alone

NCT06848946 · Status: RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 132

Last updated 2026-01-21

No results posted yet for this study

Summary

This trial will evaluate the safety and IOP -lowering efficacy of administering an iDose TR (travoprost intracameral implant) in conjunction with cataract surgery compared to cataract surgery alone

Conditions

  • Glaucoma, Open-angle
  • Ocular Hypertension (OHT)
  • Phacoemulsification Cataract Surgery

Interventions

COMBINATION_PRODUCT

iDose TR (travoprost intracameral implant) 75 µg in conjunction with cataract surgery

iDose TR (travoprost intracameral implant) 75 µg in conjunction with cataract surgery

PROCEDURE

Sham procedure in conjunction with cataract surgery

Sham procedure in conjunction with cataract surgery

Sponsors & Collaborators

  • Glaukos Corporation

    lead INDUSTRY

Principal Investigators

  • Study Director · Glaukos Corporation

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
45 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-01-13
Primary Completion
2026-08-31
Completion
2027-06-30
FDA Drug
Yes
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06848946 on ClinicalTrials.gov